Canaan funds detail Tyra Biosciences (TYRA) share ownership levels

Rhea-AI Filing Summary

Tyra Biosciences, Inc. received an amended Schedule 13G from Canaan investment entities reporting beneficial ownership of its common stock. Canaan XI L.P. directly holds 2,930,444 shares, representing approximately 5.5% of the outstanding common stock, with Canaan Partners XI LLC deemed to beneficially own the same amount as its general partner.

Canaan 2020+ Co-Investment L.P. - Series 7 directly owns 443,885 shares, or about 0.8% of the outstanding shares, with Canaan Partners 2020+ Co-Investment LLC deemed to beneficially own the same. These percentages are based on 53,372,098 shares outstanding as of October 31, 2025. Each reporting person has sole voting and dispositive power over its reported shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Tyra Biosciences, Inc.

(Name of Issuer)

COMMON STOCK, $0.0001 PAR VALUE PER SHARE

(Title of Class of Securities)

90240B106

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 90240B106

1

Names of Reporting Persons

Canaan XI L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,930,444.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,930,444.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,930,444.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Based on 53,372,098 shares of Common Stock outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025.

SCHEDULE 13G

CUSIP No. 90240B106

1

Names of Reporting Persons

Canaan Partners XI LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,930,444.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,930,444.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,930,444.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Based on 53,372,098 shares of Common Stock outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025.

SCHEDULE 13G

CUSIP No. 90240B106

1

Names of Reporting Persons

Canaan 2020+ Co-Investment L.P. - Series 7

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 443,885.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 443,885.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

443,885.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.8 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Based on 53,372,098 shares of Common Stock outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025.

SCHEDULE 13G

CUSIP No. 90240B106

1

Names of Reporting Persons

Canaan Partners 2020+ Co-Investment LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 443,885.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 443,885.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

443,885.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.8 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Based on 53,372,098 shares of Common Stock outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tyra Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 2656 State Street, Carlsbad, CA 92008
Item 2.
(a)	Name of person filing: (i) Canaan XI L.P., a Cayman Islands limited partnership ( "Canaan XI"); (ii) Canaan Partners XI LLC, a Delaware limited liability company ("Canaan XI GP"); (iii) Canaan 2020+ Co-Investment L.P. - Series 7, a Delaware limited partnership ("Canaan Series 7"); and (iv) Canaan Partners 2020+ Co-Investment, LLC, a Delaware limited liability company ("Canaan 2020+GP").
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is 855 Oak Grove, Suite 201, Menlo Park, California 94025.
(c)	Citizenship: See Item 2(a) above.
(d)	Title of class of securities: COMMON STOCK, $0.0001 PAR VALUE PER SHARE
(e)	CUSIP No.: 90240B106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Canaan XI directly owns 2,930,444 shares of Common Stock, which represents approximately 5.5% of the outstanding shares of Common Stock. (ii) Canaan XI GP is the general partner of Canaan XI and may be deemed to beneficially own 2,930,444 shares of Common Stock, which represents approximately 5.5% of the outstanding shares of Common Stock. (iii) Canaan Series 7 directly owns 443,885 shares of Common Stock, which represents approximately 0.8% of the outstanding shares of Common Stock. (iv) Canaan 2020+ GP is the general partner of Canaan Series 7 and may be deemed to beneficially own 443,885 shares of Common Stock, which represents approximately 0.8% of the outstanding shares of Common Stock.
(b)	Percent of class: The percent of class of the outstanding shares of Common Stock beneficially owned by the Reporting Persons in Item 4(a) are based on 53,372,098 shares of Common Stock outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025. %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Canaan XI: 2,930,444 shares of Common Stock; (2) Canaan XI GP: 2,930,444 shares of Common Stock; (3) Canaan Series 7: 443,885 shares of Common Stock; and (4) Canaan 2020+ GP: 443,885 shares of Common Stock.
	(ii) Shared power to vote or to direct the vote: None.
	(iii) Sole power to dispose or to direct the disposition of: (1) Canaan XI: 2,930,444 shares of Common Stock; (2) Canaan XI GP: 2,930,444 shares of Common Stock; (3) Canaan Series 7: 443,885 shares of Common Stock; and (4) Canaan 2020+ GP: 443,885 shares of Common Stock.
	(iv) Shared power to dispose or to direct the disposition of: None.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Canaan XI L.P.

Signature:	/s/ Nancy Levenson
Name/Title:	Nancy Levenson, Attorney-in-Fact
Date:	02/13/2026

Canaan Partners XI LLC

Signature:	/s/ Nancy Levenson
Name/Title:	Nancy Levenson, Attorney-in-Fact
Date:	02/13/2026

Canaan 2020+ Co-Investment L.P. - Series 7

Signature:	/s/ Nancy Levenson
Name/Title:	Nancy Levenson, Attorney-in-Fact
Date:	02/13/2026

Canaan Partners 2020+ Co-Investment LLC

Signature:	/s/ Nancy Levenson
Name/Title:	Nancy Levenson, Attorney-in-Fact
Date:	02/13/2026

FAQ

What ownership in Tyra Biosciences (TYRA) does Canaan XI L.P. report?

Canaan XI L.P. reports beneficial ownership of 2,930,444 shares of Tyra Biosciences common stock, representing approximately 5.5% of the outstanding shares, based on 53,372,098 shares outstanding as of October 31, 2025, as disclosed in the company’s Quarterly Report on Form 10-Q.

What stake in Tyra Biosciences (TYRA) does Canaan 2020+ Co-Investment L.P. - Series 7 hold?

Canaan 2020+ Co-Investment L.P. - Series 7 directly owns 443,885 shares of Tyra Biosciences common stock. This holding represents about 0.8% of the company’s outstanding shares, calculated using 53,372,098 shares outstanding as of October 31, 2025, per Tyra’s Form 10-Q disclosure.

How much voting and dispositive power do the Canaan entities report over Tyra Biosciences (TYRA) shares?

Each Canaan entity reports sole voting and sole dispositive power over its shares. Canaan XI and its general partner each report sole power over 2,930,444 shares, while Canaan Series 7 and its general partner each report sole power over 443,885 shares, with no shared voting or dispositive authority.

On what share count are the reported ownership percentages in Tyra Biosciences (TYRA) based?

The ownership percentages are based on 53,372,098 shares of Tyra Biosciences common stock outstanding as of October 31, 2025. This figure comes from the issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025.

What type of filing did the Canaan entities submit for Tyra Biosciences (TYRA)?

The Canaan entities submitted an Amendment No. 2 to Schedule 13G for Tyra Biosciences common stock. This filing reports their beneficial ownership positions as of the event date of December 31, 2025, and includes details on share counts, percentages, and voting and dispositive powers.

Who signed the amended beneficial ownership report for Tyra Biosciences (TYRA)?

The amended beneficial ownership report was signed by Nancy Levenson as Attorney-in-Fact. She signed separately for each reporting person, certifying that the information provided about share ownership and related details is true, complete, and correct as of the stated certification date.